BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-138@catalystbrief.girapphe.com
DTSTAMP:20261117T181605Z
LAST-MODIFIED:20261117T181605Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Suzhou Suncadia Biopharmaceuticals Co.\, Ltd. — SHR-A191
 2 Injection [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Phase 3 Clinical Study of SHR-A19
 12 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma.\
 nSource: https://clinicaltrials.gov/study/NCT06929624\nhttps://catalystbri
 ef.girapphe.com/e/138?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/138?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
